Menu Search
Equities

Ascendis Pharma A/S

ASND:NSQ

Ascendis Pharma A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)129.81
  • Today's Change7.17 / 5.85%
  • Shares traded640.00k
  • 1 Year change+39.58%
  • Beta0.6571
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Ascendis Pharma A/S grew revenues 421.20% from 51.17m to 266.72m while net income improved from a loss of 583.19m to a smaller loss of 481.45m.
Gross margin84.82%
Net profit margin-130.26%
Operating margin-96.44%
Return on assets-43.36%
Return on equity--
Return on investment-93.14%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Ascendis Pharma A/S fell by 52.60m. However, Cash Flow from Investing totalled 286.47m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 467.36m for operations while cash generated from financing totalled 134.29m.
Cash flow per share-7.45
Price/Cash flow per share--
Book value per share-1.67
Tangible book value per share-1.74
More ▼

Balance sheet in EURView more

Ascendis Pharma A/S has a Debt to Total Capital ratio of 114.08%.
Current ratio1.16
Quick ratio0.8448
Total debt/total equity--
Total debt/total capital1.14
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.